Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4167 - The comparison between TP53 gene polymorphisms (c.[215G > C]) homozygotes and heterozygotes in breast cancer patients: a clinicopathological analysis

Date

10 Oct 2016

Session

Poster display

Presenters

Joanna Huszno

Citation

Annals of Oncology (2016) 27 (6): 545-551. 10.1093/annonc/mdw393

Authors

J. Huszno1, E. Grzybowska2, Z. Kolosza3, M. Nycz Bochenek4, J. Pamula Pilat5, K. Tecza5, E. Nowara1

Author affiliations

  • 1 Clinical And Experimental Oncology Departament,, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
  • 2 Cwnter Fot Translational Research And Molecular Biology Of Cancer, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
  • 3 Department Of Epidemiology And Silesia Cancer Registry, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
  • 4 Genetic Outpatient Clinic, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
  • 5 Canter Fot Translational Research And Molecular Biology Of Cancer, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
More

Resources

Abstract 4167

Background

TP53 is a tumor suppressor gene which participates in regulation of cell cycle check points, DNA repair, and apoptosis. Somatic mutations of TP53 are more frequent in advanced stage or in cancer subtypes with aggressive behavior (such as triple negative or HER2-amplified breast cancers). The aim of this study was to compare TP53 germline gene polymorphisms (c.[215G > C]) wild – type homozygotes GG with heterozygotes GC according to clinicopathological factors.

Methods

We reviewed the medical records of 65 (29% TP53 gene homozygotes and 71% heterozygotes) breast cancer patients who were diagnosed and treated in COI in Gliwice. Mutation profile was assessed by RFLP-PCR technique. We evaluated the presence of polymorphism TP53 (c.[215G > C]). Statistical analysis was carried out using STATISTICA 7 software.

Results

The median age of patients was 51 years (range from 32 to 77). There was no difference according to median age between TP53 gene homozygotes and heterozygotes (51 vs. 52 years, p = 0.903). Lobular invasive carcinoma was observed insignificantly more frequently in TP53 gene homozygotes in comparison to heterozygotes (21% vs. 9%, p = 0.218). Tumor size (T3-T4) was detected in 15% of pts. Pts being TP53 gene heterozygotes had larger tumor size (T > 2) than homozygotes (20% vs. 5%, p = 0.258). Ki67 > 20% was detected in 56% of tumors and was more often reported in TP53 gene homozygotes (75% vs. 46%, p = 0.157). There was observed tendency to the presence of lymph node metastases (53% vs. 35%, p = 0.266) and triple negative breast cancer (16% vs. 7%, p = 0.347) in patients with TP53 gene homozygotes in comparison to heterozygotes (53% vs. 35%, p = 0.266). There were no associations between type of TP53 gene polymorphisms (homozygotes vs. heterozygotes) and steroid receptor status (68% vs. 74%, p = 0.762), higher histological grade (G > 2) (38% vs. 35%, p = 1.00) or HER2 overexpression (26% vs. 21%, p = 0.761).

Conclusions

TP53 gene homozygotes were characterized by lymph node metastases, lobular histological type, triple negative breast cancer and higher Ki67 (>20%). In contrary, larger tumor size (T > 2) was mostly presented in TP53 gene heterozygotes.

Clinical trial identification

Legal entity responsible for the study

Clinical and Experimental Oncology Department MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch

Funding

Center for Translational Research and Molecular Biology of Cancer Clinical and Experimental Oncology Department MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings